ИММУНОГИСТОХИМИЧЕСКИЕ ИССЛЕДОВАНИЯ В ДИАГНОСТИКЕ КОЛОРЕКТАЛЬНОГО РАКА И РОЛЬ МАРКЕРА ПРОЛИФЕРАЦИИ Ki-67
Введение: в статье представлены литературные данные, посвященные изучению роли биомаркеров в диагностике колоректального рака. На основании анализа современных научных публикаций, найденных в базах данных доказательной медицины, на настоящий момент накоплен обширный научный массив данных, позволяющих обоснованно подходить к выбору метода лечения.
Цель: проведение систематического поиска научной информации по иммуногистохимическим исследованиям, используемым для диагностики колоректального рака, а также по роли маркера пролиферации Ki-67.
Материалы и методы. Для достижения поставленной цели был выполнен систематический поиск литературы в базах данных доказательной медицины. Всего было найдено 4342 научных источников, из которых 55 были отобраны для последующего анализа.
Результаты: имеется доказательная база по роли COX2, HER2, SMAD4, ALDH1 и Ki-67 в диагностике колоректального рака.
Выводы: значение уровней экспрессии маркера пролиферации Ki-67 при колоректальном раке остается малоизученным, а доступные литературные источники зачастую содержат противоречивые данные. Проведение дополнительных клинических исследований по выявлению связей между индексом экспрессии Ki-67 и клинико-морфологическими характеристиками опухоли, а также по установлению его прогностической роли при колоректальном раке, продолжает оставаться актуальным
Куанткан Т. Жабагин, http://orcid.org/0000-0002-4304-5132
Юлия М. Семенова, http://orcid.org/0000-0003-1324-7806
Маржан А. Даулетьярова, http://orcid.org/0000-0001-8178-4051
Зухра А. Манамбаева, http://orcid.org/0000-0001-9542-3222
Нургуль К. Жумыкбаева http://orcid.org/0000-0001-5627-4877
Нурлыбек Керемханұлы, http://orcid.org/0000-0002-9924-2856
Мухтаргазы Е. Тулеутаев, http://orcid.org/0000-0002-9237-2199
Коркем С. Салыкбаева, http://orcid.org/0000-0003-3398-3595
Александра А. Селиверстова, http://orcid.org/0000-0002-1677-0830
Жанар Н. Елемесова, http://orcid.org/0000-0003-3503-5097
Государственный медицинский университет города Семей,
г. Семей, Казахстан
1. Гржибовский А.М., Иванов С.В. Поперечные (одномоментные) исследования в здравоохранении // Наука и здравоохранение. - 2015. №2. С. 5-18.
2. Клинический протокол диагностики и лечения злокачественных новообразований ободочной кишки. - №14. – Рекомендован Экспертным Советом РЦРЗ от 30 октября 2015 г.
3. Ahlem B., Wided A., Amani L., Nadia Z., Amira A., Faten F. Study of Ki67 and CD10 expression as predictive factors of recurrence of ameloblastoma // Eur Ann Otorhinolaryngol Head Neck Dis. 2015 Nov;132(5):275-9.
4. Aziz S., Wik E., Knutsvik G., Klingen T.A., Chen Y., Davidsen B., Aas H., Aas T., Akslen L.A. Evaluation of Tumor Cell Proliferation by Ki-67 Expression and Mitotic Count in Lymph Node Metastases from Breast Cancer // PLoS One. 2016 Mar 8;11(3):e0150979.
5. Bleckmann A., Conradi L.C., Menck K., Schmick N.A., Schubert A., Rietkötter E., Arackal J., Middel P., Schambony A., Liersch T., Homayounfar K., Beißbarth T., Klemm F., Binder C., Pukrop T. β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases // Clin Exp Metastasis. 2016. Apr; 33(4): 309-23.
6. Böger C., Behrens H.M., Röcken C. Ki67--An unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneity // J Surg Oncol. 2016 Jan;113(1):46-54.
7. Chen H., Hu Y., Xiang W., Cai Y., Wang Z., Xiao Q., Liu Y., Li Q., Ding K. Prognostic significance of matrix metalloproteinase 7 immunohistochemical expression in colorectal cancer: a meta-analysis // Int J Clin Exp Med. 2015. Mar 15;8(3):3281-90.
8. Chen J., Xia Q., Jiang B., Chang W., Yuan W., Ma Z., Liu Z., Shu X. Prognostic Value of Cancer Stem Cell Marker ALDH1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis // PLoS One. 2015 Dec 18;10(12):e0145164.
9. Chen Q., Zhang X., Li W.M., Ji Y.Q., Cao H.Z., Zheng P. Prognostic value of LGR5 in colorectal cancer: a meta-analysis // PLoS One. 2014 Sep 5;9(9):e107013.
10. Chen X., Dong W., Wang J., Lyu X., Lei H., Liu Y. Cyclooxygenase-2 -765G>C polymorphism and susceptibility to colorectal cancer: a meta-analysis // Zhonghua Yu Fang Yi Xue Za Zhi. 2014 Jan;48(1):62-6.
11. de Azambuja E., Cardoso F., de Castro G. Jr., Colozza M, Mano M.S., Durbecq V., Sotiriou C., Larsimont D., Piccart-Gebhart M.J. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients // Br J Cancer. 2007 May 21;96(10):1504-13.
12. Deng Y., Zhou J., Fang L., Cai Y., Ke J., Xie X., et al. ALDH1 is an independent prognostic factor for patients with stages II–III rectal cancer after receiving radiochemotherapy. British journal of cancer. 2014;110(2): 430–434.
13. Dowsett M., Nielsen T.O., A'Hern R., Bartlett J., Coombes R.C., Cuzick J., Ellis M., Henry N.L., Hugh J.C., Lively T., McShane L., Paik S., Penault-Llorca F., Prudkin L., Regan M., Salter J., Sotiriou C., Smith I.E., Viale G., Zujewski J.A., Hayes D.F. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group // J Natl Cancer Inst. 2011. Nov 16;103(22):1656-64.
14. Elzagheid A., Emaetig F., Alkikhia L., Buhmeida A., Syrjänen K., El-Faitori O., Latto M., Collan Y., Pyrhönen S. High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer // Anticancer Res. 2013 Aug;33(8):3137-43.
15. Fu H., Qi L., Chen L., He Y., Zhang N., Guo H. Expression of Ovol2 is related to epithelial characteristics and shows a favorable clinical outcome in hepatocellular carcinoma // Onco Targets Ther. 2016 Sep 29;9:5963-5973.
16. Gissi D.B., Gabusi A., Tarsitano A., Badiali G., Marchetti C., Morandi L., Foschini M.P., Montebugnoli L. Ki67 Overexpression in mucosa distant from oral carcinoma: A poor prognostic factor in patients with long-term follow-up // J Craniomaxillofac Surg. 2016 Sep;44(9):1430-5.
17. Goossens-Beumer I.J., Zeestraten ECM, Benard A., Christen T., Reimers M.S., Keijzer R., et al. Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. British journal of cancer. 2014;110(12): 2935–2944.
18. Grossman H.B., Tangen C.M., Cordon-Cardo C., Cote R., Waldman F.M., De Vere White R.W., Karnad A.B., Glode M., Crawford E.D. Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study // Oncol Rep. 2006 Oct;16(4):807-10.
19. Hayashi H., Beppu T., Sakamoto Y., Miyamoto Y., Yokoyama N., Higashi T., Nitta H., Hashimoto D., Chikamoto A., Baba H. Prognostic value of Ki-67 expression in conversion therapy for colorectal liver-limited metastases // Am J Cancer Res. 2015 Feb 15;5(3):1225-33.
20. He X., Chen Z., Jia M., Zhao X. Downregulated E-cadherin expression indicates worse prognosis in Asian patients with colorectal cancer: evidence from meta-analysis // PLoS One. 2013 Jul 29;8(7):e70858.
21. Hsi E.D., Jung S.H., Lai R., Johnson J.L., Cook J.R., Jones D, Devos S., Cheson B.D., Damon L.E., Said J. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study // Leuk Lymphoma. 2008 Nov;49(11):2081-90.
22. Huang L., Ren F., Tang R., Feng Z., Chen G. Prognostic Value of Expression of Cyclin E in Gastrointestinal Cancer: ASystematic Review and Meta-Analysis // Technol Cancer Res Treat. 2016 Feb;15(1):12-9.
23. Kang W.K., Lee J.K., Oh S.T., Lee S.H., Jung C.K. Stromal expression of miR-21 in T3-4a colorectal cancer is an independent predictor of early tumor relapse // BMC Gastroenterol. 2015 Jan 22;15:2.
24. Kántor O., Cserpán D., Völgyi B., Lukáts Á., Somogyvári Z. The Retinal TNAP // Subcell Biochem. 2015;76:107-23.
25. Kim H.S., Park S., Koo J.S., Kim S., Kim J.Y., Nam S., Park H.S., Kim S.I., Park B.W. Risk Factors Associated with Discordant Ki-67 Levels between Preoperative Biopsy and Postoperative Surgical Specimens in Breast Cancers // PLoS One. 2016 Mar 8;11(3):e0151054.
26. Kim N.K., Park J.K., Shin E., Kim Y.W. The combination of nuclear factor kappa B, cyclo-oxygenase-2 and vascular endothelial growth factor expression predicts poor prognosis in stage II and III colorectal cancer // Anticancer Res. 2014 Nov;34(11):6451-7.
27. Kunzmann A.T., Murray L.J., Cardwell C.R., McShane C.M, .McMenamin U.C, Cantwell M.M. PTGS2 (Cyclooxygenase-2) expression and survival among colorectal cancer patients: a systematic review // Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1490-7.
28. Liu Y., Yin W., Yan T., Du Y., Shao Z., Lu J. The clinical significance of Ki-67 as a marker of prognostic value and chemosensitivity prediction in hormone-receptor-positive breast cancer: a meta-analysis of the published literature // Curr Med Res Opin. 2013 Nov;29(11):1453-61.
29. Martins S.F., Amorim R., Mota S.C., Costa L., Pardal F., Rodrigues M., Longatto-Filho A. Ki-67 Expression in CRC Lymph Node Metastasis Does Not Predict Survival // Biomed Res Int. 2015;2015:131685.
30. Melling N., Kowitz C.M., Simon R., Bokemeyer C., Terracciano L., Sauter G., Izbicki J.R., Marx A.H. High Ki67 expression is an independent good prognostic marker in colorectalcancer // J Clin Pathol. 2016 Mar;69(3):209-14.
31. Nowak K., Casey J., Chitale A., Kalchman I., Buss E., Keith S.W., Hegarty S.E., Curtis M., Solomides C., Shi W., Judy K.D., Andrews D.W., Farrell C.J., Werner-Wasik M. High KI67 Labeling Index in Resected WHO Grade 1 Meningiomas Correlates With a Higher Rate of Recurrence // Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E572.
32. O'Dwyer D., Ralton L.D., O'Shea A., Murray G.I. The proteomics of colorectal cancer: identification of a protein signature associated with prognosis. PloS one. 2011;6(11): e27718.
33. Ormenisan C., Kubik M., Legrand S., Kraemer D., Smotherman C., Masood S. The potential of ki67 and p53 assessment in development of individualized targeted therapy in breast cancer patients // Pathologica. 2015 Sep-Dec;107(3-4):177-80.
34. Pap Z., Ilyés I.Á., Mocan S.L., Dénes L., Muică Nagy-Bota M.C., Pávai Z., Szántó A. Changes in immunoexpression of p53, Ki-67, Ets-1, APAF-1 and PTEN in serrated and conventional colon adenomas // Rom J Morphol Embryol. 2015;56(4):1389-96.
35. Papagiorgis P.C. Segmental distribution of some common molecular markers for colorectal cancer(CRC): influencing factors and potential implications // Tumour Biol. 2016 May;37(5):5727-34.
36. Pascale M., Aversa C., Barbazza R., Marongiu B., Siracusano S., Stoffel F., Sulfaro S., Roggero E., Bonin S., Stanta G. The proliferation marker Ki67, but not neuroendocrine expression, is an independent factor in the prediction of prognosis of primary prostate cancer patients //Radiol Oncol. 2016 Jul 19;50(3):313-20.
37. Peng L., Zhou Y., Wang Y., Mou H., Zhao Q. Prognostic significance of COX-2 immunohistochemical expression in colorectal cancer: a meta-analysis of the literature // PLoS One. 2013;8(3):e58891.
38. Petrelli F., Viale G., Cabiddu M., Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients // Breast Cancer Res Treat. 2015 Oct;153(3):477-91.
39. Preusser M., Hoeftberger R., Woehrer A., Gelpi E., Kouwenhoven M., Kros J.M., Sanson M., Idbaih A., Brandes A.A., Heinzl H., Gorlia T., Hainfellner J.A., van den Bent M. Prognostic value of Ki67 index in anaplastic oligodendroglial tumours--a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group // Histopathology. 2012 May;60(6):885-94.
40. Pyo J.S., Kang G., Cho W.J., Choi S.B. Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non-small cell lung cancers: A meta-analysis // Pathol Res Pract. 2016 Aug;212(8):710-6.
41. Pyo J.S., Kang G., Park K. Clinicopathological significance and diagnostic accuracy of HER2 immunohistochemistry in colorectal cancer: A meta-analysis // Int J Biol Markers. 2016 Apr 18:0.
42. Sen A., Mitra S., Das R.N., Dasgupta S., Saha K., Chatterjee U., Mukherjee K., Datta C., Chattopadhyay B.K. Expression of CDX-2 and Ki-67 in different grades of colorectal adenocarcinomas // Indian J Pathol Microbiol. 2015 Apr-Jun;58(2):158-62.
43. Shomaf M., Yousef A.L., Ababna N., Bobali Y. Cyclooxygenase-2 (COX2) gene polymorphisms and the risk of sporadiccolorectal cancer and polyps among Jordanian population // Turk J Gastroenterol. 2015 Mar; 26(2):154-8.
44. Sorski L., Melamed R., Matzner P., Lavon H., Shaashua L., Rosenne E., Ben-Eliyahu S. Reducing liver metastases of colon cancer in the context of extensive and minor surgeries through β-adrenoceptors blockade and COX2 inhibition // Brain Behav Immun. 2016 May 25. pii: S0889-1591(16)30138-6.
45. Sostres C., Gargallo C.J., Lanas A. Aspirin, cyclooxygenase inhibition and colorectal cancer // World J. Gastrointest. Pharmacol. Ther. – 2.14. – 5 (1): 40–9.
46. Sunpaweravong S., Puttawibul P., Sunpaweravong P., Nitiruangjaras A., Boonyaphiphat P., Kemapanmanus M. Correlation between Serum SCCA and CYFRA 2 1-1, Tissue Ki-67, and Clinicopathological Factors in Patients with Esophageal Squamous Cell Carcinoma //J Med Assoc Thai. 2016 Mar;99(3):331-7.
47. Verhoven B., Yan Y., Ritter M., Khor L.Y, Hammond E., Jones C., Amin M., Bahary J.P., Zeitzer K., Pollack A. Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08 // Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):317-23.
48. Voorneveld P.W, Jacobs R.J., Kodach L.L., Hardwick J.C. A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer // Transl Oncol. 2015 Feb;8(1):18-24.
49. Wang J., Guo X., Zhang J., Song J., Ji. M, Yu S., Wang J, Cao Z, Dong W. Cyclooxygenase-2 polymorphisms and susceptibility to colorectal cancer: a meta-analysis // Yonsei Med J. 2013 Nov;54(6):1353-61.
50. World Cancer Report. — 2014. — С. 17.
51. Wu S.W., Ma C.C., Li W.H. Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis // Diagn Pathol. 2015 Aug 16;10:144.
52. Wu T., Zhang W., Yang G., Li H., Chen Q., Song R., Zhao L. HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review // Oncotarget. 2016 Jul 6.
53. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, García FA, Gillman MW, Harper DM, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Owens DK, Phillips WR, Phipps MG, Pignone MP, Siu AL. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement // JAMA. 2016 Jun 21;315(23):2564-75.
54. Zhang G., Xie W., Liu Z., Lin C., Piao Y., Xu L., Guo F., Xie X. Prognostic function of Ki-67 for pathological complete response rate of neoadjuvant chemotherapy in triple-negative breast cancer // Tumori. 2014 Mar-Apr;100(2):136-42.
55. Zhao L., Yu N., Guo T., Hou Y., Zeng Z., Yang X., Hu P., Tang X., Wang J., Liu M. Tissue biomarkers for prognosis of prostate cancer: a systematic review and meta-analysis // Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):1047-54.
References:
1. Grjibovski A.M., Ivanov S.V. Poperechnye (odnomomentnye) issledovaniya v zdravookhranenii [Cross-sectional studies in health sciences]. Nauka i Zdravoohranenie [Science & Healthcare]. 2015. №2. pp. 5-18. [in Russian]
2. Klinicheskii protokol diagnostiki i lecheniya zlokachestvennykh novoobrazovanii obodochnoi kishki. - №14. – Rekomendovan Ekspertnym Sovetom RTsRZ ot 30 oktyabrya [Clinical protocol on colorectal cancer management. - №14. – Adopted by the Exper Committee of RCRZ at October, 30t]. 2015. [in Russian]
3. Ahlem B., Wided A., Amani L., Nadia Z., Amira A., Faten F. Study of Ki67 and CD10 expression as predictive factors of recurrence of ameloblastoma. Eur Ann Otorhinolaryngol Head Neck Dis. 2015 Nov;132(5):275-9.
4. Aziz S., Wik E., Knutsvik G., Klingen T.A., Chen Y., Davidsen B., Aas H., Aas T., Akslen L.A. Evaluation of Tumor Cell Proliferation by Ki-67 Expression and Mitotic Count in Lymph Node Metastases from Breast Cancer. PLoS One. 2016 Mar 8;11(3):e0150979.
5. Bleckmann A., Conradi L.C., Menck K., Schmick N.A., Schubert A., Rietkötter E., Arackal J., Middel P., Schambony A., Liersch T., Homayounfar K., Beißbarth T., Klemm F., Binder C., Pukrop T. β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases. Clin Exp Metastasis. 2016. Apr; 33(4): 309-23.
6. Böger C., Behrens H.M., Röcken C. Ki67--An unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneity. J Surg Oncol. 2016 Jan;113(1):46-54.
7. Chen H., Hu Y., Xiang W., Cai Y., Wang Z., Xiao Q., Liu Y., Li Q., Ding K. Prognostic significance of matrix metalloproteinase 7 immunohistochemical expression in colorectal cancer: a meta-analysis. Int J Clin Exp Med. 2015. Mar 15;8(3):3281-90.
8. Chen J., Xia Q., Jiang B., Chang W., Yuan W., Ma Z., Liu Z., Shu X. Prognostic Value of Cancer Stem Cell Marker ALDH1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. PLoS One. 2015 Dec 18;10(12):e0145164.
9. Chen Q., Zhang X., Li W.M., Ji Y.Q., Cao H.Z., Zheng P. Prognostic value of LGR5 in colorectal cancer: a meta-analysis. PLoS One. 2014 Sep 5;9(9):e107013.
10. Chen X., Dong W., Wang J., Lyu X., Lei H., Liu Y. Cyclooxygenase-2 -765G>C polymorphism and susceptibility to colorectal cancer: a meta-analysis. Zhonghua Yu Fang Yi Xue Za Zhi. 2014 Jan;48(1):62-6.
11. de Azambuja E., Cardoso F., de Castro G. Jr., Colozza M, Mano M.S., Durbecq V., Sotiriou C., Larsimont D., Piccart-Gebhart M.J. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007 May 21;96(10):1504-13.
12. Deng Y., Zhou J., Fang L., Cai Y., Ke J., Xie X., et al. ALDH1 is an independent prognostic factor for patients with stages II–III rectal cancer after receiving radiochemotherapy. British journal of cancer. 2014;110(2): 430–434.
13. Dowsett M., Nielsen T.O., A'Hern R., Bartlett J., Coombes R.C., Cuzick J., Ellis M., Henry N.L., Hugh J.C., Lively T., McShane L., Paik S., Penault-Llorca F., Prudkin L., Regan M., Salter J., Sotiriou C., Smith I.E., Viale G., Zujewski J.A., Hayes D.F. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011. Nov 16;103(22):1656-64.
14. Elzagheid A., Emaetig F., Alkikhia L., Buhmeida A., Syrjänen K., El-Faitori O., Latto M., Collan Y., Pyrhönen S. High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer. Anticancer Res. 2013 Aug;33(8):3137-43.
15. Fu H., Qi L., Chen L., He Y., Zhang N., Guo H. Expression of Ovol2 is related to epithelial characteristics and shows a favorable clinical outcome in hepatocellular carcinoma. Onco Targets Ther. 2016 Sep 29;9:5963-5973.
16. Gissi D.B., Gabusi A., Tarsitano A., Badiali G., Marchetti C., Morandi L., Foschini M.P., Montebugnoli L. Ki67 Overexpression in mucosa distant from oral carcinoma: A poor prognostic factor in patients with long-term follow-up. J Craniomaxillofac Surg. 2016 Sep;44(9):1430-5.
17. Goossens-Beumer I.J., Zeestraten ECM, Benard A., Christen T., Reimers M.S., Keijzer R., et al. Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. British journal of cancer. 2014;110(12): 2935–2944.
18. Grossman H.B., Tangen C.M., Cordon-Cardo C., Cote R., Waldman F.M., De Vere White R.W., Karnad A.B., Glode M., Crawford E.D. Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study. Oncol Rep. 2006 Oct;16(4):807-10.
19. Hayashi H., Beppu T., Sakamoto Y., Miyamoto Y., Yokoyama N., Higashi T., Nitta H., Hashimoto D., Chikamoto A., Baba H. Prognostic value of Ki-67 expression in conversion therapy for colorectal liver-limited metastases. Am J Cancer Res. 2015 Feb 15;5(3):1225-33.
20. He X., Chen Z., Jia M., Zhao X. Downregulated E-cadherin expression indicates worse prognosis in Asian patients with colorectal cancer: evidence from meta-analysis. PLoS One. 2013 Jul 29;8(7):e70858.
21. Hsi E.D., Jung S.H., Lai R., Johnson J.L., Cook J.R., Jones D, Devos S., Cheson B.D., Damon L.E., Said J. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma. 2008 Nov;49(11):2081-90.
22. Huang L., Ren F., Tang R., Feng Z., Chen G. Prognostic Value of Expression of Cyclin E in Gastrointestinal Cancer: ASystematic Review and Meta-Analysis. Technol Cancer Res Treat. 2016 Feb;15(1):12-9.
23. Kang W.K., Lee J.K., Oh S.T., Lee S.H., Jung C.K. Stromal expression of miR-21 in T3-4a colorectal cancer is an independent predictor of early tumor relapse. BMC Gastroenterol. 2015 Jan 22;15:2.
24. Kántor O., Cserpán D., Völgyi B., Lukáts Á., Somogyvári Z. The Retinal TNAP. Subcell Biochem. 2015;76:107-23.
25. Kim H.S., Park S., Koo J.S., Kim S., Kim J.Y., Nam S., Park H.S., Kim S.I., Park B.W. Risk Factors Associated with Discordant Ki-67 Levels between Preoperative Biopsy and Postoperative Surgical Specimens in Breast Cancers. PLoS One. 2016 Mar 8;11(3):e0151054.
26. Kim N.K., Park J.K., Shin E., Kim Y.W. The combination of nuclear factor kappa B, cyclo-oxygenase-2 and vascular endothelial growth factor expression predicts poor prognosis in stage II and III colorectal cancer. Anticancer Res. 2014 Nov;34(11):6451-7.
27. Kunzmann A.T., Murray L.J., Cardwell C.R., McShane C.M, .McMenamin U.C, Cantwell M.M. PTGS2 (Cyclooxygenase-2) expression and survival among colorectal cancer patients: a systematic review. Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1490-7.
28. Liu Y., Yin W., Yan T., Du Y., Shao Z., Lu J. The clinical significance of Ki-67 as a marker of prognostic value and chemosensitivity prediction in hormone-receptor-positive breast cancer: a meta-analysis of the published literature. Curr Med Res Opin. 2013 Nov;29(11):1453-61.
29. Martins S.F., Amorim R., Mota S.C., Costa L., Pardal F., Rodrigues M., Longatto-Filho A. Ki-67 Expression in CRC Lymph Node Metastasis Does Not Predict Survival. Biomed Res Int. 2015;2015:131685.
30. Melling N., Kowitz C.M., Simon R., Bokemeyer C., Terracciano L., Sauter G., Izbicki J.R., Marx A.H. High Ki67 expression is an independent good prognostic marker in colorectalcancer. J Clin Pathol. 2016 Mar;69(3):209-14.
31. Nowak K., Casey J., Chitale A., Kalchman I., Buss E., Keith S.W., Hegarty S.E., Curtis M., Solomides C., Shi W., Judy K.D., Andrews D.W., Farrell C.J., Werner-Wasik M. High KI67 Labeling Index in Resected WHO Grade 1 Meningiomas Correlates With a Higher Rate of Recurrence. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E572.
32. O'Dwyer D., Ralton L.D., O'Shea A., Murray G.I. The proteomics of colorectal cancer: identification of a protein signature associated with prognosis. PloS one. 2011;6(11): e27718.
33. Ormenisan C., Kubik M., Legrand S., Kraemer D., Smotherman C., Masood S. The potential of ki67 and p53 assessment in development of individualized targeted therapy in breast cancer patients. Pathologica. 2015 Sep-Dec;107(3-4):177-80.
34. Pap Z., Ilyés I.Á., Mocan S.L., Dénes L., Muică Nagy-Bota M.C., Pávai Z., Szántó A. Changes in immunoexpression of p53, Ki-67, Ets-1, APAF-1 and PTEN in serrated and conventional colon adenomas. Rom J Morphol Embryol. 2015;56(4):1389-96.
35. Papagiorgis P.C. Segmental distribution of some common molecular markers for colorectal cancer(CRC): influencing factors and potential implications. Tumour Biol. 2016 May;37(5):5727-34.
36. Pascale M., Aversa C., Barbazza R., Marongiu B., Siracusano S., Stoffel F., Sulfaro S., Roggero E., Bonin S., Stanta G. The proliferation marker Ki67, but not neuroendocrine expression, is an independent factor in the prediction of prognosis of primary prostate cancer patients. Radiol Oncol. 2016 Jul 19;50(3):313-20.
37. Peng L., Zhou Y., Wang Y., Mou H., Zhao Q. Prognostic significance of COX-2 immunohistochemical expression in colorectal cancer: a meta-analysis of the literature. PLoS One. 2013;8(3):e58891.
38. Petrelli F., Viale G., Cabiddu M., Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat. 2015 Oct;153(3):477-91.
39. Preusser M., Hoeftberger R., Woehrer A., Gelpi E., Kouwenhoven M., Kros J.M., Sanson M., Idbaih A., Brandes A.A., Heinzl H., Gorlia T., Hainfellner J.A., van den Bent M. Prognostic value of Ki67 index in anaplastic oligodendroglial tumours--a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Histopathology. 2012 May;60(6):885-94.
40. Pyo J.S., Kang G., Cho W.J., Choi S.B. Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non-small cell lung cancers: A meta-analysis. Pathol Res Pract. 2016 Aug;212(8):710-6.
41. Pyo J.S., Kang G., Park K. Clinicopathological significance and diagnostic accuracy of HER2 immunohistochemistry in colorectal cancer: A meta-analysis. Int J Biol Markers. 2016 Apr 18:0.
42. Sen A., Mitra S., Das R.N., Dasgupta S., Saha K., Chatterjee U., Mukherjee K., Datta C., Chattopadhyay B.K. Expression of CDX-2 and Ki-67 in different grades of colorectal adenocarcinomas. Indian J Pathol Microbiol. 2015 Apr-Jun;58(2):158-62.
43. Shomaf M., Yousef A.L., Ababna N., Bobali Y. Cyclooxygenase-2 (COX2) gene polymorphisms and the risk of sporadiccolorectal cancer and polyps among Jordanian population. Turk J Gastroenterol. 2015 Mar; 26(2):154-8.
44. Sorski L., Melamed R., Matzner P., Lavon H., Shaashua L., Rosenne E., Ben-Eliyahu S. Reducing liver metastases of colon cancer in the context of extensive and minor surgeries through β-adrenoceptors blockade and COX2 inhibition. Brain Behav Immun. 2016 May 25. pii: S0889-1591(16)30138-6.
45. Sostres C., Gargallo C.J., Lanas A. Aspirin, cyclooxygenase inhibition and colorectal cancer. World J. Gastrointest. Pharmacol. Ther. 2.14. 5 (1): 40–9.
46. Sunpaweravong S., Puttawibul P., Sunpaweravong P., Nitiruangjaras A., Boonyaphiphat P., Kemapanmanus M. Correlation between Serum SCCA and CYFRA 2 1-1, Tissue Ki-67, and Clinicopathological Factors in Patients with Esophageal Squamous Cell Carcinoma. J Med Assoc Thai. 2016 Mar;99(3):331-7.
47. Verhoven B., Yan Y., Ritter M., Khor L.Y, Hammond E., Jones C., Amin M., Bahary J.P., Zeitzer K., Pollack A. Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08. Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):317-23.
48. Voorneveld P.W, Jacobs R.J., Kodach L.L., Hardwick J.C. A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer. Transl Oncol. 2015 Feb;8(1):18-24.
49. Wang J., Guo X., Zhang J., Song J., Ji. M, Yu S., Wang J, Cao Z, Dong W. Cyclooxygenase-2 polymorphisms and susceptibility to colorectal cancer: a meta-analysis. Yonsei Med J. 2013 Nov;54(6):1353-61.
50. World Cancer Report. 2014. Р. 17.
51. Wu S.W., Ma C.C., Li W.H. Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis. Diagn Pathol. 2015 Aug 16;10:144.
52. Wu T., Zhang W., Yang G., Li H., Chen Q., Song R., Zhao L. HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review. Oncotarget. 2016 Jul 6.
53. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, García FA, Gillman MW, Harper DM, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Owens DK, Phillips WR, Phipps MG, Pignone MP, Siu AL. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2016 Jun 21;315(23):2564-75.
54. Zhang G., Xie W., Liu Z., Lin C., Piao Y., Xu L., Guo F., Xie X. Prognostic function of Ki-67 for pathological complete response rate of neoadjuvant chemotherapy in triple-negative breast cancer. Tumori. 2014 Mar-Apr;100(2):136-42.
55. Zhao L., Yu N., Guo T., Hou Y., Zeng Z., Yang X., Hu P., Tang X., Wang J., Liu M. Tissue biomarkers for prognosis of prostate cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):1047-54.
Количество просмотров: 530
Категория статей:
Обзор литературы
Библиографическая ссылка
Жабагин К.Т., Семенова Ю.М., Даулетьярова М.А., Манамбаева З.А., Жумыкбаева Н.К., Керемханұлы Н., Тулеутаев М.Е., Салыкбаева К.С., Селиверстова А. А. Елемесова Ж.Н. Иммуногистохимические исследования в диагностике колоректального рака и роль маркера пролиферации Ki-67 / / Наука и Здравоохранение. 2016. № 5. С. 150-163. Zhabagin K.T., Semenova Yu.М., Dauletyarova М.А., Manambaeva Z.А., Zhumykbaeva N.К. Keremkhanuly N., Tuleutaev М.Е., Salykbaeva К.S., Seliverstova А.А., Elemesova Zh.N. Immunohistochemistry in diagnostics of colorectal cancer and the role of proliferation marker Ki-67. Nauka i Zdravookhranenie [Science & Healthcare]. 2016, 5, pp. 150-163. Жабагин К.Т., Семенова Ю.М., Даулетьярова М.А., Манамбаева З.А., Жумыкбаева Н.К., Керемханұлы Н., Тулеутаев М.Е., Салыкбаева К.С., Селиверстова А. А. Елемесова Ж.Н. Колоректальді ракты диагностикалаудағы иммуногистохимиялық тексерулер мен Ki-67 пролиферация маркерінің рөлі / / Ғылым және Денсаулық сақтау. 2016. № 5. Б. 150-163.Похожие публикации:
ДИАГНОСТИЧЕСКАЯ И ТЕРАПЕВТИЧЕСКАЯ ЛАПАРОСКОПИЯ ПРИ ТРАВМАХ ЖИВОТА. ОБЗОР ЛИТЕРАТУРЫ.
КАЧЕСТВО ЖИЗНИ И МЕТОДЫ ЕГО ОЦЕНКИ ПРИ ПЕРВИЧНОМ БИЛИАРНОМ ХОЛАНГИТЕ
ЛЕКАРСТВЕННО-ИНДУЦИРОВАННЫЕ ПОРАЖЕНИЯ ПЕЧЕНИ И ГЕНДЕРНЫЕ РАЗЛИЧИЯ
INTERRELATION OF INTRAABDOMINAL HYPERTENSION AND MARKERS OF GASTROINTESTINAL TRACT INJURY IN PATIENTS WITH MULTIORGAN DYSFUNCTION
НОВЫЕ СИНДРОМЫ И ПАТТЕРНЫ ОСТРОЙ ОККЛЮЗИИ КОРОНАРНЫХ АРТЕРИЙ. ОБЗОР ЛИТЕРАТУРЫ.